Navigation Links
Pharmatek Laboratories Expands GMP Manufacturing Capabilities
Date:10/4/2010

SAN DIEGO, Oct. 4 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities.  The company has purchased two roller compactors, a pilot-scale Vector TFC-220 roller compactor with a rate of 20 kg/hour, and a Vector TFC-LAB Micro lab-scale roller compactor with a rate of 1 kg/hour.  Both machines have been integrated into Pharmatek's GMP facility and are ready for GMP manufacturing.

"The addition of roller compaction expands our granulation capability, especially in the area of moisture sensitive and density-challenged API's.  When used in conjunction with our microdose capsule filling technology (Xcelodose 600S and Symyx Powdernium MTM2005), roller compaction also provides an option for larger fill weights in powder-in-capsule dosage forms," said Kevin Rosenthal, Director of Manufacturing.  "Additionally, with the purchase of two roller compactors we now have dry granulation capability in our highly-potent and non-highly-potent manufacturing facilities."

Pharmatek has also complemented existing manufacturing capacities by expanding single-batch blending size capabilities three-fold (up to 36kg) with the acquisition of a 3 cu. ft. V-blender, and increasing capsule and tablet production by purchasing a Bosch GKF400 automated encapsulator with a rate of 23,000 capsules/hour and a Korsch PH-106 instrumented tablet press with rate of 32,400 tablets/hour.

"With the roller compactors, Pharmatek can now support a broad range of solid oral formulations that previously were not optimal or feasible using our existing wet granulation equipment due to moisture sensitivity.  The 3 cu. ft. V-blender and Bosch encapsulator have positioned us well for large-scale Phase II clinical trial manufacturing," stated Jeff Bibbs, CEO and CSO of Pharmatek.  "Also, by expanding our existing encapsulation and tablet manufacturing capabilities, we can better serve our clients' clinical drug supply needs as they move beyond small-scale development and transition to GMP manufacture of drug product for clinical trials."

For a complete listing of Pharmatek's manufacturing equipment and capabilities, please visit www.pharmatek.com/gmp-manufacturing.html.

About Pharmatek Laboratories, Inc.Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry.  Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.

Statements contained in this media release which are not historical facts may constitute forward-looking statements.  All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion.  The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc.  Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.Company Contact:Ryan Lane, Marketing CoordinatorPharmatek Laboratories, Inc.(858) 805-6383 x284rlane@pharmatek.comAvailable Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jeffrey A. Bibbs

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=48157

Timothy M. Scott

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=50335


'/>"/>

SOURCE Pharmatek Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
2. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
5. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
6. Romark Laboratories Raises $18 Million in Institutional Financing
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
10. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
11. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):